1. Home
  2. PHAR vs MCB Comparison

PHAR vs MCB Comparison

Compare PHAR & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • MCB
  • Stock Information
  • Founded
  • PHAR 1988
  • MCB 1999
  • Country
  • PHAR Netherlands
  • MCB United States
  • Employees
  • PHAR N/A
  • MCB N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • MCB Major Banks
  • Sector
  • PHAR Health Care
  • MCB Finance
  • Exchange
  • PHAR Nasdaq
  • MCB Nasdaq
  • Market Cap
  • PHAR 731.1M
  • MCB 694.8M
  • IPO Year
  • PHAR N/A
  • MCB 2017
  • Fundamental
  • Price
  • PHAR $10.00
  • MCB $73.21
  • Analyst Decision
  • PHAR Strong Buy
  • MCB Buy
  • Analyst Count
  • PHAR 3
  • MCB 3
  • Target Price
  • PHAR $30.00
  • MCB $76.33
  • AVG Volume (30 Days)
  • PHAR 3.6K
  • MCB 101.2K
  • Earning Date
  • PHAR 07-31-2025
  • MCB 07-17-2025
  • Dividend Yield
  • PHAR N/A
  • MCB N/A
  • EPS Growth
  • PHAR N/A
  • MCB N/A
  • EPS
  • PHAR N/A
  • MCB 5.92
  • Revenue
  • PHAR $320,708,000.00
  • MCB $270,555,000.00
  • Revenue This Year
  • PHAR $13.31
  • MCB $11.02
  • Revenue Next Year
  • PHAR $7.68
  • MCB $12.86
  • P/E Ratio
  • PHAR N/A
  • MCB $12.40
  • Revenue Growth
  • PHAR 24.13
  • MCB 12.84
  • 52 Week Low
  • PHAR $6.65
  • MCB $40.21
  • 52 Week High
  • PHAR $12.61
  • MCB $75.60
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 43.61
  • MCB 67.68
  • Support Level
  • PHAR $9.99
  • MCB $73.19
  • Resistance Level
  • PHAR $10.59
  • MCB $75.13
  • Average True Range (ATR)
  • PHAR 0.35
  • MCB 1.94
  • MACD
  • PHAR -0.14
  • MCB 0.28
  • Stochastic Oscillator
  • PHAR 7.45
  • MCB 78.27

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: